Therapeutics development benefits substantially from physiologically relevant assays, ideally ones using disease-relevant cells or organoids. Cell-based assays in small-molecule drug discovery have traditionally relied on stable cell lines to deliver consistent assay performance at screening scale. However, stable cell line development can be costly and time consuming. For protein or cell-based immunotherapeutic discovery, phage display is considered the gold standard, but its long selection cycles and complex downstream development can create bottlenecks. In this webinar, James Brady will discuss an advanced transfection technology that enables the development of faster, more flexible cell-based screening assays.
Topics to be covered:
- Streamlining assay development through increased speed and reproducibility
- A faster, more adaptable alternative to traditional stable cell lines, transiently transfected assay ready cells
- Accelerating antibody and cell therapy discovery with mammalian display screening
Thursday, June 26th, 2025 | 12:00 PM - 1:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
James Brady, PhD
Senior Vice President of Technical Applications & Customer Support
MaxCyte, Inc.
